Ampril 30 tablet 2,5mg & 5mg & 10mg Ramipril Амприл

Ampril Indications

treatment, including in complex therapy:

- arteriat hypertension;
- congestive heart failure;
- patients with clinical signs of congestive heart failure in the first few days after an acute myocardial infarction;
- diabetic or non-diabetic nephropathy.

Reducing the risk of myocardial infarction, stroke and cardiovascular death in patients at high risk of cardiovascular disease, including coronary artery disease (whether myocardial infarction), stroke and peripheral artery disease.

Dosage & Administration

Dosage and duration of treatment depend on the condition of the patient's needs and the possible use of other drugs, so determined individually.

Treatment of hypertension
The recommended starting dose of ramipril to patients who are not taking diuretics and which do not have heart failure was 2.5 mg 1 time per day. Depending upon the response to treatment dose can be increased by 2 times every 2-3 weeks. The usual maintenance dose is 2.5-5 mg / day and the maximum daily dose - 10 mg.
If the patient is taking diuretics, it is necessary for the possibility to cancel or at least reduce the dose of at least 2-3 days prior to initiation of treatment with ramipril
The initial dose of ramipril to patients with hypertension who were taking the diuretic before starting treatment, as well as for patients with hypertension and heart failure with impaired renal function or not is 1.25 mg 1 time per day. Treatment is initiated in hospital under close medical supervision.

Contradictions

Hypersensitivity to ramipril or to any other component of the drug, as well as other ACE inhibitors, the drug, the presence of angioedema in history, renal artery stenosis (bilateral or stenosis of the artery to a solitary kidney), hypotension or hemodynamically unstable condition, primary aldosteronism.

AMF should be avoided or other ACE inhibitors in combination with extracorporal methods of therapy, which can cause blood contacting with the negatively charged surfaces because when there is a risk of severe anaphylactoid reaction that sometimes may lead to severe anaphylactic shock.

Thus, when it is impossible for the reception AMPR dialysis or hemofiltration using poly (acrylonitrile, 2-sodium metilsulfonatnyh) ultrafiltration membranes with high activity (e.g. 69 AN) and LDL apheresis procedure with dextran sulfate.